Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo

Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health said today that the FDA accepted its resubmitted new drug application for their “smart pill”. The drug-device product combines Abilify and a Proteus ingestible sensor in a single tablet.

The FDA is slated to make a decision on the NDA resubmission in the 4th quarter this year.

Get the full story at our sister site, Drug Delivery Business News.

The post Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo appeared first on MassDevice.

from MassDevice http://ift.tt/2qKR8Dc